首页> 外文期刊>Cornea >Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.
【24h】

Tear concentration and safety of levofloxacin ophthalmic solution 1.5% compared with ofloxacin ophthalmic solution 0.3% after topical administration in healthy adult volunteers.

机译:健康成人志愿者局部用药后左氧氟沙星滴眼液的泪液浓度和安全性为1.5%,而氧氟沙星滴眼液的泪液浓度和安全性为0.3%。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: This study evaluated the tear concentration and safety of levofloxacin ophthalmic solution 1.5%. METHODS: Healthy adult volunteers (N = 125) received a single initial two-drop bilateral dose of either levofloxacin 1.5% (n = 100) or ofloxacin 0.3% (n = 25). Tear-fluid drug concentrations were measured at 15 minutes and at 2, 6, 12, and 24 hours after dosing. Subjects were dosed every 2 hours while awake and 4 and 6 hours after retiring (Days 1-3) and four times daily while awake (Days 4-14). Final measurements and evaluations were done on Day 15. Tear concentrations were determined by high-performance liquid chromatography. Safety and tolerability parameters included visual acuity, ophthalmoscopy, biomicroscopy, rose bengal staining, and adverse effects. RESULTS: Tear concentrations after a single two-drop dose of levofloxacin 1.5% and ofloxacin 0.3% were above 2 microg/mL, a concentration that exceeds the minimum inhibitory concentration90 for levofloxacin in typical ocular bacterial pathogens at all time points through 24 hours. The area under the curve for the first 12 hours for levofloxacin 1.5% was 2703.5 +/- 574.22 microg.h/mL and 414.1 +/- 1179.00 microg.h/mL with ofloxacin 0.3%. Maximal concentrations were 806.9 +/- 8.57 and 73.3 +/- 165.46 microg/mL, respectively. Levofloxacin 1.5% and ofloxacin 0.3% did not differ in adverse event incidence, except for transient mild/moderate dysgeusia (14% of levofloxacin-treated subjects versus 4% of ofloxacin-treated subjects). No corneal epithelial damage or inflammatory changes were associated with levofloxacin. CONCLUSION: A single dose of levofloxacin 1.5% produced tear fluid concentrations that were well above the minimum inhibitory concentration90 for typical ocular pathogens and was safe and well tolerated.
机译:目的:本研究评估了1.5%左氧氟沙星滴眼液的泪液浓度和安全性。方法:健康的成人志愿者(N = 125)接受了一次初始的两滴双侧双剂左氧氟沙星1.5%(n = 100)或氧氟沙星0.3%(n = 25)。在给药后15分钟和2、6、12和24小时测量泪液药物浓度。受试者在清醒时每2小时,退休后4至6小时(第1-3天)和清醒时(四至14天)每天给药四次。在第15天进行最终测量和评估。通过高效液相色谱法测定泪液浓度。安全性和耐受性参数包括视敏度,检眼镜,生物显微镜检查,玫瑰红染色和不良反应。结果:单次两滴左氧氟沙星1.5%和氧氟沙星0.3%的滴眼液后泪液浓度高于2 microg / mL,该浓度超过了24小时内所有时间点典型眼细菌病原体中左氧氟沙星的最低抑菌浓度90。左氧氟沙星1.5%在开始12小时的曲线下面积为2703.5 +/- 574.22 microg.h / mL和含0.3%氧氟沙星的414.1 +/- 1179.00 microg.h / mL。最大浓度分别为806.9 +/- 8.57和73.3 +/- 165.46 microg / mL。左氧氟沙星1.5%和氧氟沙星0.3%的不良事件发生率没有差异,除了短暂的轻度/中度消化不良(左氧氟沙星治疗的受试者为14%,氧氟沙星治疗的受试者为4%)。左氧氟沙星无角膜上皮损伤或炎症变化。结论:单剂1.5%的左氧氟沙星产生的泪液浓度远高于典型眼病原体的最低抑制浓度90,并且安全且耐受性良好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号